Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction

Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

OBJECTIVES: We determined the influence of angiotensin I-converting enzyme (ACE) insertion (I)/deletion (D) polymorphism on the extent of myocardial ischemia in patients with acute myocardial infarction. BACKGROUND: The I/D polymorphism, which in part controls plasma and tissue expression of ACE, has been implicated in predisposition to myocardial infarction and ventricular remodeling. METHODS: I/D genotyping, predischarge adenosine-thallium-201 perfusion tomography and radionuclide angiography were performed in 113 patients (72 men, 41 women) with a diagnosis of acute myocardial infarction. A subgroup of 96 patients also underwent coronary angiography. RESULTS: Genotypes DD, ID and II were present in 27, 56 and 30 patients, respectively. There was no significant difference in the baseline characteristics of patients, total creatine kinase, peak MB fraction, Killip class, mean ejection fraction or the number of diseased vessels in patients with the DD, ID or II genotype. However, the size of the total and the reversible perfusion defects was greater in those with DD than in those with ID or II genotype (total defect size [mean +/- SD] 33.7 +/- 22.5%, 29.5 +/- 19.2% and 22.2 +/- 16.0%, respectively [p = 0.022]; reversible defect size 18.0 +/- 16.0%, 12.1 +/- 11.6% and 8.2 +/- 7.8%, respectively [p = 0.006]). Occlusion of the infarct-related artery was also more common in patients with DD genotype (odds ratio 3.9, 95% confidence interval 1.4 to 11.0). Multivariate analysis showed that the I/D genotype was an independent predictor of perfusion defect size and patency of the infarct-related artery (p = 0.001). CONCLUSIONS: DD genotype was associated with a larger ischemic defect and occlusion of the infarct-related artery. Patients with DD genotype, having a larger ischemic defect, are expected to be at a greater risk for subsequent cardiovascular events.

This article has been cited by other articles:

				W. S. Weintraub and S. Sadanandan Percutaneous Coronary Intervention in Stable Patients After Acute Myocardial Infarction Circulation, September 16, 2003; 108(11): 1292 - 1294. [Full Text] [PDF]

				D. S. Jacoby and D. J. Rader Renin-Angiotensin System and Atherothrombotic Disease: From Genes to Treatment Arch Intern Med, May 26, 2003; 163(10): 1155 - 1164. [Abstract] [Full Text] [PDF]

				B.-q. Zhu, R. E Sievers, A. E. Browne, R. J Lee, K. Chatterjee, W. Grossman, J. S Karliner, and W. W Parmley Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function Journal of Renin-Angiotensin-Aldosterone System, March 1, 2003; 4(1): 31 - 37. [Abstract] [PDF]

				B.-q. Zhu, Y.-p. Sun, R. E. Sievers, A. E. M. Browne, S. Pulukurthy, K. Sudhir, R. J. Lee, T. M. Chou, K. Chatterjee, and W. W. Parmley Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion J. Am. Coll. Cardiol., March 1, 2000; 35(3): 787 - 795. [Abstract] [Full Text] [PDF]

				A. J. Marian, F. Safavi, L. Ferlic, J. K. Dunn, A. M. Gotto, and C. M. Ballantyne Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: The lipoprotein and coronary atherosclerosis study J. Am. Coll. Cardiol., January 1, 2000; 35(1): 89 - 95. [Abstract] [Full Text] [PDF]

				A. Okamura, M. Ohishi, H. Rakugi, T. Katsuya, Y. Yanagitani, S. Takiuchi, Y. Taniyama, K. Moriguchi, H. Ito, Y. Higashino, et al. Pharmacogenetic Analysis of the Effect of Angiotensin-Converting Enzyme Inhibitor on Restenosis After Percutaneous Transluminal Coronary Angioplasty Angiology, October 1, 1999; 50(10): 811 - 822. [Abstract] [PDF]

				M. Pfohl, M. Koch, S. Prescod, K.K. Haase, H.U. Haring, and K.R. Karsch Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study Eur. Heart J., September 2, 1999; 20(18): 1318 - 1325. [Abstract] [PDF]

				D. Henrion, J. Benessiano, I. Philip, S. Vuillaumier-Barrot, M. Iglarz, G. Plantefeve, D. Chatel, U. Hvass, G. Durand, J.-M. Desmonts, et al. The deletion genotype of the angiotensin I-converting enzyme is associated with an increased vascular reactivity in vivo and in vitro J. Am. Coll. Cardiol., September 1, 1999; 34(3): 830 - 836. [Abstract] [Full Text] [PDF]